Quarterly report [Sections 13 or 15(d)]

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

v3.25.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Operating expenses:        
Research and development $ 14,521,342 $ 535,162 $ 19,528,283 $ 1,214,964
General and administrative expenses 1,287,783 1,766,010 4,633,883 3,470,133
Total operating expenses 15,809,125 2,301,172 24,162,166 4,685,097
Loss from operations (15,809,125) (2,301,172) (24,162,166) (4,685,097)
Other income (expense):        
Loss on debt conversion with related party     (6,134,120)  
Interest income, net 80,582 20,488 44,871 63,245
Exchange loss, net (17,509)   (36,251)  
Total other income (expense) 63,073 20,488 (6,125,500) 63,245
Loss before income taxes (15,746,052) (2,280,684) (30,287,666) (4,621,852)
Deferred income tax benefit (expense) 1,436 0 (189,255) 0
Net loss (15,744,616) (2,280,684) (30,476,921) (4,621,852)
Accrual of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock     (1,256,662)  
Net loss attributable to common stockholders $ (15,744,616) $ (2,280,684) $ (31,733,583) $ (4,621,852)
Net loss per common share, basic (in dollars per share) $ (8.2) $ (2.05) $ (18.02) $ (4.95)
Net loss per common share, diluted (in dollars per share) $ (8.2) $ (2.05) $ (18.02) $ (4.95)
Weighted average number of shares outstanding - basic (in shares) 1,919,433 1,110,317 1,761,237 932,872
Weighted average number of shares outstanding - diluted (in shares) 1,919,433 1,110,317 1,761,237 932,872
Comprehensive loss        
Net loss $ (15,744,616) $ (2,280,684) $ (30,476,921) $ (4,621,852)
Foreign currency translation adjustment (1,368,846)   2,226,852  
Comprehensive loss $ (17,113,462) $ (2,280,684) $ (28,250,069) $ (4,621,852)